Genetic Modifiers Regulating DNA Replication and Double-strand Break Repair Are Associated with Differences in Mammary Tumors in Mouse Models of Li-Fraumeni Syndrome
Overview
Authors
Affiliations
Breast cancer is the most common tumor among women with inherited variants in the TP53 tumor suppressor, but onset varies widely suggesting interactions with genetic or environmental factors. Rodent models haploinsufficent for Trp53 also develop a wide variety of malignancies associated with Li-Fraumeni syndrome, but BALB/c mice are uniquely susceptible to mammary tumors and is genetically linked to the Suprmam1 locus on chromosome 7. To define mechanisms that interact with deficiencies in p53 to alter susceptibility to mammary tumors, we fine mapped the Suprmam1 locus in females from an N2 backcross of BALB/cMed and C57BL/6J mice. A major modifier was localized within a 10 cM interval on chromosome 7. The effect of the locus on DNA damage responses was examined in the parental strains and mice that are congenic for C57BL/6J alleles on the BALB/cMed background (SM1-Trp53). The mammary epithelium of C57BL/6J-Trp53 females exhibited little radiation-induced apoptosis compared to BALB/cMed-Trp53 and SM1-Trp53 females indicating that the Suprmam1 alleles could not rescue repair of radiation-induced DNA double-strand breaks mostly relying on non-homologous end joining. In contrast, the Suprmam1 alleles in SM1-Trp53 mice were sufficient to confer the C57BL/6J-Trp53 phenotypes in homology-directed repair and replication fork progression. The Suprmam1 alleles in SM1-Trp53 mice appear to act in trans to regulate a panel of DNA repair and replication genes which lie outside the locus.
The levels of p53 govern the hierarchy of DNA damage tolerance pathway usage.
Castano B, Schorer S, Guo Y, Calzetta N, Gottifredi V, Wiesmuller L Nucleic Acids Res. 2024; 52(7):3740-3760.
PMID: 38321962 PMC: 11039994. DOI: 10.1093/nar/gkae061.
SEOM clinical guideline on heritable TP53-related cancer syndrome (2022).
Sanchez-Heras A, Ramon Y Cajal T, Pineda M, Aguirre E, Grana B, Chirivella I Clin Transl Oncol. 2023; 25(9):2627-2633.
PMID: 37133731 PMC: 10425559. DOI: 10.1007/s12094-023-03202-9.
Genetic modifiers of p53: opportunities for breast cancer therapies.
Majhi P, Sharma A, Jerry D Oncotarget. 2023; 14:236-241.
PMID: 36961913 PMC: 10038353. DOI: 10.18632/oncotarget.28387.
Kordon E, Lanari C, Mando P, Novaro V, Rossi M, Simian M J Mammary Gland Biol Neoplasia. 2021; 26(3):227-234.
PMID: 34642841 PMC: 8510571. DOI: 10.1007/s10911-021-09501-7.
Mego M, Svetlovska D, Reckova M, Angelis D, Kalavska K, Obertova J Invest New Drugs. 2021; 39(6):1664-1670.
PMID: 34052929 DOI: 10.1007/s10637-021-01130-5.